| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-90074-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-97348-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-50475-0.025ml | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor Plus 488 | NBP3-11994AFP488 | |||
| Alexa Fluor Plus 555 | NBP3-11994AFP555 | |||
| Alexa Fluor Plus 594 | NBP3-11994AFP594 | |||
| Alexa Fluor Plus 647 | NBP3-11994AFP647 | |||
| Alexa Fluor Plus 680 | NBP3-11994AFP680 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-11994-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-81270SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2645-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-52687-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35241-1mg | |||
| Carrier-Free | NBP2-35241-100ug | |||
| Carrier-Free | NBP2-35241-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-75193-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-75908-0.025mg | |||
![Flow Cytometry: CD160 Antibody (275) [NBP2-90074] - Analysis of Human CD160 expression on human whole blood lymphocytes. Cells were stained with purified anti-Human CD160, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes.](http://images.novusbio.com/fullsize/CD160-Antibody-275-Flow-Cytometry-NBP2-90074-img0001.jpg "Flow Cytometry: CD160 Antibody (275) [NBP2-90074] - Analysis of Human CD160 expression on human whole blood lymphocytes. Cells were stained with purified anti-Human CD160, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes.")
![Immunohistochemistry-Paraffin: IKK alpha Antibody [NBP2-97348] - Immunochemical staining of human IKK alpha in human kidney with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.](http://images.novusbio.com/fullsize/IKK-alpha-Antibody-Immunohistochemistry-Paraffin-NBP2-97348-img0001.jpg "Immunohistochemistry-Paraffin: IKK alpha Antibody [NBP2-97348] - Immunochemical staining of human IKK alpha in human kidney with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.")
![Flow Cytometry: CD2 Antibody (LT2) [NBP3-09147] - Analysis (surface staining) of human peripheral blood cells with anti-human CD2 (LT2) purified, GAM-APC.](http://images.novusbio.com/fullsize/CD2-Antibody-LT2-Flow-Cytometry-NBP3-09147-img0001.jpg "Flow Cytometry: CD2 Antibody (LT2) [NBP3-09147] - Analysis (surface staining) of human peripheral blood cells with anti-human CD2 (LT2) purified, GAM-APC.")
![Flow Cytometry: CD3 Antibody (MM1A) [NBP2-60876] - Obtained with bovine leukocytes](http://images.novusbio.com/fullsize/CD3-Antibody-MM1A-Flow-Cytometry-NBP2-60876-img0001.jpg "Flow Cytometry: CD3 Antibody (MM1A) [NBP2-60876] - Obtained with bovine leukocytes")
![Western Blot: CCR4 Antibody (KW-0761 (Mogamulizumab)) - Chimeric [NBP2-81270] - Western Blot using CCR4 Antibody (KW-0761 (Mogamulizumab)) [NBP2-81270]. Human brain cerebellum (A) and human heart (B) lysates (35ug protein in RIPA buffer) were resolved on a 10% SDS PAGE gel and blots probed with the chimeric rabbit IgG version of KW-0761 [NBP2-81270] at 2 ug/ml before detection using an anti-rabbit secondary antibody. A primary incubation of 1h was used and protein was detected by chemiluminescence. The expected running size for CCR4 is 37.7kDa.](http://images.novusbio.com/fullsize/CCR4-Antibody-KW-0761-Mogamulizumab-Chimeric-Western-Blot-NBP2-81270-img0001.jpg "Western Blot: CCR4 Antibody (KW-0761 (Mogamulizumab)) - Chimeric [NBP2-81270] - Western Blot using CCR4 Antibody (KW-0761 (Mogamulizumab)) [NBP2-81270]. Human brain cerebellum (A) and human heart (B) lysates (35ug protein in RIPA buffer) were resolved on a 10% SDS PAGE gel and blots probed with the chimeric rabbit IgG version of KW-0761 [NBP2-81270] at 2 ug/ml before detection using an anti-rabbit secondary antibody. A primary incubation of 1h was used and protein was detected by chemiluminescence. The expected running size for CCR4 is 37.7kDa.")
![Flow Cytometry: OX40 Ligand/TNFSF4 Antibody (R4930 (Oxelumab)) - Chimeric [NBP2-52687] - Human peripheral blood leukocytes were fixed using 2% PFA, permeabilised using 0.5% Triton and stained with unimmunized rabbit IgG antibody (isotype control, black line) or the rabbit IgG-chimeric version of R4930 (NBP2-52687, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-rabbit IgG AlexaFluor 488 antibody at a dilution of 1:1000 and cells analyzed using a FACSCanto flow-cytometer.](http://images.novusbio.com/fullsize/OX40-Ligand-TNFSF4-Antibody-R4930-Oxelumab-Chimeric-Flow-Cytometry-NBP2-52687-img0001.jpg "Flow Cytometry: OX40 Ligand/TNFSF4 Antibody (R4930 (Oxelumab)) - Chimeric [NBP2-52687] - Human peripheral blood leukocytes were fixed using 2% PFA, permeabilised using 0.5% Triton and stained with unimmunized rabbit IgG antibody (isotype control, black line) or the rabbit IgG-chimeric version of R4930 (NBP2-52687, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-rabbit IgG AlexaFluor 488 antibody at a dilution of 1:1000 and cells analyzed using a FACSCanto flow-cytometer.")
![SDS-Page: Rat IL-21 Protein [NBP2-35241]](http://images.novusbio.com/fullsize/Rat-IL-21-Protein-SDS-Page-NBP2-35241-img0001.jpg "SDS-Page: Rat IL-21 Protein [NBP2-35241]")
![Immunofluorescence: IL6R Antibody (rhPM-1 (Tocilizumab)) - Chimeric [NBP2-75193] - Immunofluorescence staining of fixed U937 cells with anti-IL-6 receptorantibody rhPM-1 (Tocilizumab). Immunofluorescence analysis of paraformaldehyde fixed U937 cells on coverslips, permeabilized with 0.15% Triton and stained with the chimeric rabbit IgG version of rhPM-1 (Tocilizumab) (NBP2-75193) at 10 ug/ml for 1h followed by Alexa Fluor 488 secondary antibody (1 ug/ml), showing membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom NBP2-75193, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-Fluorescein antibody followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/IL6R-Antibody-rhPM-1-Tocilizumab-Chimeric-Immunofluorescence-NBP2-75193-img0001.jpg "Immunofluorescence: IL6R Antibody (rhPM-1 (Tocilizumab)) - Chimeric [NBP2-75193] - Immunofluorescence staining of fixed U937 cells with anti-IL-6 receptorantibody rhPM-1 (Tocilizumab). Immunofluorescence analysis of paraformaldehyde fixed U937 cells on coverslips, permeabilized with 0.15% Triton and stained with the chimeric rabbit IgG version of rhPM-1 (Tocilizumab) (NBP2-75193) at 10 ug/ml for 1h followed by Alexa Fluor 488 secondary antibody (1 ug/ml), showing membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom NBP2-75193, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-Fluorescein antibody followed by Alexa Fluor 488 secondary antibody.")